Category: Mergers & AcquisitionsSyndicate content

BD-CareFusion deal passes US anti-trust waiting period

November 21, 2014 by Mark Hollmer

Becton Dickinson's $12.2 billion bid for device maker CareFusion clears the required waiting period under U.S. anti-trust regulations.

BD-CareFusion deal passes US anti-trust waiting period

J&J demands $7.2 billion from Boston Scientific as trial begins

November 20, 2014 by MassDevice

Johnson & Johnson wants a federal judge to make Boston Scientific cough up some $7.2 billion - 40% of Boston's market cap - over J&J's jilting by Guidant Corp.

J&J demands $7.2 billion from Boston Scientific as trial begins

Will Orange County's medtech scene lose its juice without Allergan?

November 20, 2014 by Brian Johnson

Will the $66 billion buyout of Allergan by Actavis suck some of the juice out of Orange County, Calif., which Allergan's called home for 60 years?

Will Orange County's medtech scene lose its juice without Allergan?

Smith & Nephew to sell UK plant to DelStar

November 19, 2014 by Brad Perriello

Smith & Nephew deals its wound management plant in Gilberdyke, England, to DelStar Medical for an undisclosed amount.

Smith & Nephew sells UK plant

MDT prepares $10B worth of bonds to help fund its $43B acquisition of COV | The week in medtech M&A

November 19, 2014 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Report: Medtronic readies $10B bond flotation for Covidien deal; Medtech mergers stayed strong in Q3; Sources: Philips attracts private equity bids for lighting unit; Medtronic, Covidien set timetable for shareholders meetings; Report: Actavis may buy Allergan for at least $60 billion

Report: Medtronic readies $10B bond flotation for Covidien deal

November 17, 2014 by Brad Perriello

Johnson & Johnson wants $5B from Boston Scientific for Guidant jilting

November 19, 2014 by MassDevice

Johnson & Johnson wants more than $5 billion in damages from Boston Scientific in a lawsuit brought over its 2006 jilting by Guidant Corp.

Johnson & Johnson wants $5B from Boston Scientific over Guidant jilting

Medtronic hits 52-week high on strong Q2 results

November 18, 2014 by Brad Perriello

Medtronic's strong fiscal 2nd-quarter results pushed its stock to a 52-week high today.

Medtronic hits 52-week high on strong Q2 results

Shares of Medtronic (NYSE:MDT) hit a 52-week high today on the strength of its 2nd-quarter results, peaking at $72.74 apiece.

MDT shares closed at $72.47 each, for a 4.7% gain on the day.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp